Advertisement

Picture Berlin Partner HealthCapital RegMed Forum 2018 October 600x60px
Person › Details

Simon Harnest (Cellectis Inc.)

Harnest, Simon (Cellectis 201505 VP Finance + Investor Relations before Trout Group)

 

Organisation Organisation Cellectis Inc.
  Group Cellectis (Group)
Products Product public relations / investor relations / marcom (services)
  Product 2 LIFE SCIENCES
     

Cellectis S.A.. (5/4/15). "Press Release: Cellectis S.A. Announces Calyxt is New Name for its Plant Sciences Subsidiary". Paris.

Cellectis S.A. (Alternext: ALCLS – Nasdaq Global Market: CLLS) a pioneering gene-editing company employing proprietary technologies to develop best-in-class products in the emerging field of immuno-oncology, today announced that it has changed the name of its subsidiary, Cellectis plant sciences, Inc. to Calyxt, Inc.

The name change is part of Cellectis’ effort to further distinguish the parent company’s focus from that of it subsidiary. Gene editing is the common base of the two companies: it is used by Cellectis in the development of new and innovative product candidates for treatment of cancers, and by Calyxt in the development of improved crops for consumers with healthier characteristics.

The goal of the name change is to leverage the strengths of both Cellectis and Calyxt brand identities.

To find out more about Calyxt, please visit www.calyxt.com


About Cellectis

Cellectis is a gene-editing company focused on developing immunotherapies based on gene edited engineered CAR-T cells (UCART). The company’s mission is to develop a new generation of cancer therapies based on engineered T-cells. Cellectis capitalizes on its 15 years of expertise in genome engineering – based on its flagship TALEN® products and meganucleases and pioneering electroporation PulseAgile technology – to create a new generation of immunotherapies. CAR technologies are designed to target surface antigens expressed on cells. Using its life-science-focused, pioneering genomeengineering technologies, Cellectis’ goal is to create innovative products in multiple fields and with various target markets. Cellectis S.A. is listed on the Nasdaq Global Market (ticker: CLLS) and on the NYSE Alternext market (ticker: ALCLS). To find out more about us, visit our website: www.cellectis.com


For further information, please contact:

Media contacts
Jennifer Moore, Director of Communications
Phone: 917-580-1088
email: media@cellectis.com

BMC Communications
Brad Miles
Phone: 646-513-3125
email: bmiles@bmccommunications.com

IR contacts
Simon Harnest, VP Finance and Investor Relations
Phone: 646-385-9008
email: simon.harnest@cellectis.com

   
Record changed: 2018-04-16

Advertisement

Picture Berlin Partner HealthCapital RegMed Forum 2018 October 600x60px


More documents for Simon Harnest


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture EBD Group BIO-Europe 2018 Copenhagen Denmark Partnerships 600x60px




» top